R413
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 60
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.410
- CHOLESTEROL_HOMEOSTASIS+0.400
- FATTY_ACID_METABOLISM+0.390
- GLYCOLYSIS+0.350
- E2F_TARGETS+0.300
- ANDROGEN_RESPONSE+0.290
- KRAS_SIGNALING_DN+0.270
- ESTROGEN_RESPONSE_LATE+0.250
- XENOBIOTIC_METABOLISM+0.230
- BILE_ACID_METABOLISM+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.310
- MYC_TARGETS_V1-0.250
- WNT_BETA_CATENIN_SIGNALING-0.250
- PI3K_AKT_MTOR_SIGNALING-0.220
- TGF_BETA_SIGNALING-0.220
- ALLOGRAFT_REJECTION-0.190
- OXIDATIVE_PHOSPHORYLATION-0.170
- ANGIOGENESIS-0.160
- P53_PATHWAY-0.160
- DNA_REPAIR-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303732 | — | — | 0.635 |
| 2 | MNG1244 | — | — | 0.627 |
| 3 | MNG223 | — | — | 0.604 |
| 4 | MNG821 | — | — | 0.575 |
| 5 | 0ef944a9-2a51-4518-8a4f-4e7226248061 | — | — | 0.574 |
| 6 | R326 | — | — | 0.547 |
| 7 | R213 | — | — | 0.536 |
| 8 | R382 | — | — | 0.532 |
| 9 | TCGA-BA-4077-01B-01R-1436-07 | — | — | 0.529 |
| 10 | MNG209 | — | — | 0.523 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.160 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |